Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q3 2025
Kiniksa Pharmaceuticals International (KNSA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $181M for the third quarter 2025 (Q3 2025), +61% from a year earlier and +15% from the quarter before. Operating margin was 13.3%, net earnings $18.4M (10.2% of revenue).
Kiniksa Pharmaceuticals International, Q3 2025: revenue $181M (+61% year over year), operating margin 13.3%, net earnings $18.4M, operating cash flow $33.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $181M | +15% | +61% |
| Operating profit | $24.0M | +19% | — |
| Net earnings | $18.4M | +3% | — |
| Operating cash flow | $33.7M | +20% | — |
| Free cash flow | $33.0M | +18% | — |
What changed
Revenue was $180.9M in Q3 2025, up 61% year over year and up 15% from the previous quarter.
Operating profit was $24.0M, a 13.3% margin (up 21.9 points year over year). Total costs grew 29% against revenue growth of 61%. The fastest-growing cost line was Other operating costs (+116%). Net earnings were $18.4M. The effective tax rate was 32.1%.
Operating cash flow was $33.7M, 183% of net earnings. Non-cash charges added back $384K of depreciation and amortization and $10.1M of share-based compensation. Working capital and other items added $4.7M. Capital expenditures of $671K left free cash flow of $33.0M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the third quarter 2025?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $181M for the third quarter 2025 (Q3 2025), +61% from a year earlier and +15% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the third quarter 2025?
Operating profit was $24.0M (13.3% of revenue) and net earnings $18.4M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.